Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Find insight on Pfizer, Roche and more in the latest Market Talks covering the Health Care sector.

Pfizer (PFE) is ending a late-stage trial of its once-daily GLP-1 pill, Danuglipron, after a participant experienced a liver ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted. Pharmaceutical titan Pfizer (NYSE: PFE) is a case in point.

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of ...

Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming ...

What Happened? A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous ...